Summary & Overview
HCPCS M1230: Reactive HCV Antibody Without Timely Viral Confirmation or Treatment
HCPCS Level II code M1230 documents patients with a reactive hepatitis C virus (HCV) antibody test who lack timely follow-up care: either no confirmatory HCV viral (RNA) test is performed, or a viral test detects viremia but the patient is not referred to an HCV-treating clinician within one month and does not start HCV treatment within three months, with no reason provided. This code captures missed opportunities in the HCV care cascade that have implications for individual outcomes and public health transmission control.
Key payers discussed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national perspective on how this code is used to flag gaps in linkage-to-care and treatment initiation after reactive HCV screening, with context on service settings and clinical implications. The publication outlines benchmarks for timely follow-up, potential policy levers payers and health systems may use to improve care transitions, and the clinical context around HCV screening, confirmatory testing, and treatment timelines. Data not available in the input for specific payer coverage policies, modifiers, taxonomies, ICD-10 mappings, and related codes.
Billing Code Overview
HCPCS Level II code M1230 describes cases where a patient has a reactive hepatitis C virus (HCV) antibody test and either does not receive a follow-up HCV viral (RNA) test, or receives a follow-up viral test that detects HCV viremia but the patient is not referred to an HCV-treating clinician within 1 month and does not have HCV treatment initiated within 3 months of the reactive antibody test, with reason not given.
-
Service type: Care coordination / follow-up management for positive HCV screening results, specifically documenting lack of timely diagnostic confirmation or treatment initiation.
-
Typical site of service: Outpatient clinical settings where HCV screening and follow-up occur, such as primary care clinics, community health centers, and outpatient specialty clinics.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 42-year-old male presents to a community clinic after routine screening with a reactive hepatitis C virus (HCV) antibody result (M1230 describes gaps in follow-up). The clinic documents the reactive antibody result in the electronic medical record. Standard clinical workflow would include ordering a confirmatory HCV RNA (viral) test, notifying the patient of the reactive antibody, and arranging linkage to an HCV-treating clinician (infectious disease, hepatology, or an experienced primary care clinician). In this scenario either no HCV RNA test was completed, or the HCV RNA test returned positive for viremia and the patient was not referred to an HCV-treating clinician within 1 month and did not have HCV treatment initiated within 3 months of the reactive antibody result. Typical sites of service include outpatient primary care clinics, federally qualified health centers, community health clinics, and laboratory facilities. Common real-world factors include missed communication of results, patient barriers to follow-up, or lack of referral processes. The clinical significance is that untreated HCV viremia carries risk of progressive liver disease and transmission; timely viral confirmation and linkage-to-care are standard quality measures in HCV screening programs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When substantially greater work is documented for administrative or linkage activities related to HCV follow-up beyond typical counseling/documentation |